Conduit Pharmaceuticals I... (CDT)
NASDAQ: CDT
· Real-Time Price · USD
0.48
-0.02 (-4.46%)
At close: May 06, 2025, 3:59 PM
0.51
6.65%
Pre-market: May 07, 2025, 05:38 AM EDT
Company Description
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility.
It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility.
The company was founded in 2019 and is based in San Diego, California.
Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Conduit Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Mar 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Andrew Regan |
Contact Details
Address: 4995 Murphy Canyon Road San Diego, California United States | |
| Website | https://www.conduitpharma.com |
Stock Details
| Ticker Symbol | CDT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000913142 |
| CUSIP Number | 20678X106 |
| ISIN Number | US20678X1063 |
| Employer ID | 36-3601505 |
| SIC Code | 3357 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Regan | Founder, Chief Executive Officer & Director |
| James Bligh | Interim Chief Financial Officer & Director |
| Dr. David Joszef Tapolczay | Head of Strategy & Licensing |
| Dr. Joanne M. Holland | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 06, 2025 | 8-K | Current Report |
| May 01, 2025 | 10-Q | Quarterly Report |
| May 01, 2025 | 8-K | Current Report |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 22, 2025 | S-3 | Filing |
| Apr 17, 2025 | 4 | Filing |
| Apr 16, 2025 | PRE 14A | Filing |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |